What is Breo Ellipta?
Breo Ellipta is a combined inhaler treatment for COPD. It contains two active ingredients — fluticasone furoate, a corticosteroid, and vilanterol trifenatate, a long-acting beta2-agonist (LABA).
Working together, these two ingredients can ease lung inflammation, improving your symptoms and allowing you to breathe more comfortably.Â
Who is Breo Ellipta for?
Breo Ellipta is prescribed for adults with COPD. COPD is the name for a group of chronic lung conditions, such as bronchitis and emphysema, and is usually treated with inhaled medications that open your airways.[1]
COPD typically affects middle-aged people over 40, but you might be more at risk of developing it if you’re a smoker. People who have a genetic condition called alpha-1 antitrypsin deficiency are also more prone to developing COPD.[2]
How does Breo Ellipta work?
Breo Ellipta works in two different ways. Fluticasone reduces inflammation in your lungs, and vilanterol helps the muscles around your airways relax. This combined action makes it easier to breathe by easing COPD symptoms.
Bronchodilators are often used to manage COPD. They can be short or long-acting and often work by combining two different medications. The effects of Breo Ellipta are designed to last 24 hours, so one daily dose should be enough to help keep your COPD symptoms under control.Â
Does Breo Ellipta come in different doses?
Breo Ellipta is available as a 100mcg/25mcg inhaler. It contains 100mcg of fluticasone and 25mcg of vilanterol.
The standard dose is one inhalation a day, and there’s never any need to use your inhaler more often than this. If you miss a dose at your usual time, you can take it as soon as you remember. But if it’s getting close to the time of your next dose, skip the missed one and carry on with your normal daily dosage routine.
How we source info.
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.